Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)
|出版商||Mordor Intelligence LLP||商品編碼||704728|
|出版日期||內容資訊||英文 114 Pages
|狂犬病(恐水症)疫苗的全球市場:成長，趨勢，及預測 Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日期: 2019年09月01日||內容資訊: 英文 114 Pages||
Rabies is a viral disease spread by the bite or scratch of an animal, however, the symptoms appear relatively slowly. In such cases, by the time, the symptoms appear, it is generally too late to save the patients. In the developed markets, the cases of human rabies is less because of more pet friendly communities and government initiatives, however, in emerging markets as well as low-income countries, there are fewer regulations to protect the people against animals bites and a large number of stray dogs can be observed across metropolitan cities as well as other cities and towns. Such factors raise the concerns regarding low protection against dog bites which raises the demand for rabies vaccines in such regions. However, limited resources, as well as negligence by government general public, are among the major causes which limit the use and adoption of rabies vaccines.
Domestic dogs are among the most common reservoir of viruses, which is regularly being checked by government initiatives adopted well across major cities and region in the world. However, still, several diagnostic tests and vaccines are given to prevent the cases of rabies across humans. The scope of the report covers the rabies vaccines market by product, vaccination type, end-user, and geography.
The Purified Chick Embryo Cell Rabies Vaccine is Estimated to Contribute Large, Over the Forecast Period
The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure. Such factors drive their importance and usage across hospitals and clinics.
North America is Estimated to Have Largest Share in the Global Market
According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.4% of the rabies cases, whereas domestic animals accounted for 48.7% cases of rabies in 2015. In the past few years, the number of human deaths attributed to rabies in the United States has declined due to two major reasons, the first one is animal control and vaccination programs. Secondly, effective human rabies vaccines and immunoglobulins have been developed over time. Similarly, major steps were taken across Canada and Mexico to protect the animals and humans rabies virus infection spread. A significant contribution by government and companies interests in this regions, makes this region, highly useful in terms of demand and use of rabies vaccines.
The major market players are focusing on technological advancements and pet care initiatives in collabroation with hospitals and government channels. Some of the major players in the market are AstraZeneca (MedImmune), GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, and Cadila Pharmaceuticals Ltd, among others.